Pharmacokinetics and pharmacodynamics of valganciclovir in infants with severe HIV-associated pneumonia in Africa: a sub-study of the EMPIRICAL randomised controlled trial
Loading...
Identifiers
Publication date
Authors
Jacobs, Tom G.
Mumbiro, Vivian
Tembo, John
Egbe, Franklin N.
Moraleda, Cinta
Advisors
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
SDG
Metrics
Abstract
Cytomegalovirus (CMV) is a major unrecognised cause of morbidity and mortality in infants living with HIV. Valganciclovir, an oral prodrug of ganciclovir, treats CMV in immunocompromised patients, but pharmacokinetic data in infants living with HIV are lacking. This study evaluated exploratory valganciclovir pharmacokinetic and pharmacodynamic outcomes in infants with severe HIV-associated pneumonia.
Description
UNESCO Subjects
Keywords
Bibliographic reference
Jacobs, T. G., Mumbiro, V., Tembo, J., Egbe, F. N., Moraleda, C., Beca, L. S. D. A. B., Passanduca, A., Kakooza, L., Chitsamatanga, M., Nduna, B., Bramugy, J., Tagarro, A., Chhaganlal, K. D., Mutesi, S., Mark, N. L., Bwakura-Dangarembizi, M., Namuzizya, N., Ballesteros, A., Dominguez-Rodríguez, S., … Manukyan, L. (2026). Pharmacokinetics and pharmacodynamics of valganciclovir in infants with severe HIV-associated pneumonia in Africa: A sub-study of the EMPIRICAL randomised controlled trial. eClinicalMedicine, 94, 103899. https://doi.org/10.1016/j.eclinm.2026.103899
Editor's version
https://doi.org/10.1016/j.eclinm.2026.103899Type of document
Collections
La licencia de este ítem se describe como Attribution 4.0 International